Company Overview and News

0
Buying dries up in Shanghai after bourse says funds tracking MSCI indexes finish building up positions

2018-06-01 scmp
About 70 per cent of the nearly 230 mainland-traded stocks that joined MSCI’s emerging markets and global indexes retreated after the Shanghai exchange said major index-based funds were done with stock purchases to track portfolio changes
0027 SMSOF SMSEY 1910 SCHYF 1928 GXYEF GXYYY SCHYY

0
Macau casino operator SJM spikes 8pc as Goldman upgrades target price ahead of hotel opening

2018-05-31 scmp
SJM Holdings, the Macau gaming operator owned by the family of casino mogul Stanley Ho, posted its biggest intra-day gain in over six years after US broker Goldman Sachs raised its target price to reflect the opening of its new flagship property, the Grand Lisboa Palace in mid-2019.
2282 SCHYF WYNMF MCHVF 0200 GXYEF GXYYY 0880 SJMHY MDEVF 1128 0027 MCHVY 1928 SJMHF SCHYY WYNMY

0
Gaming industry still a safe bet in PH amid changing rules, rising competition

2018-05-28 business.inquirer.net
In a country which is 80 percent Catholic, it would seem surprising that the gaming industry has taken off: the Philippines has become one of the key markets for casinos in Asia after Macau and Singapore.
0027 BBRRF BLOOM GXYEF GXYYY 42R

0
Macau casino operator Galaxy supports closure of Philippines island despite US$500m resort plans

2018-05-03 scmp
The casino operator also provides updates on plans for resorts in Hengqin in China and Japan
0027 506186 GLXYENT GXYEF GXYYY

0
UPDATE 1-Macau's Galaxy posts 36 pct rise in Q1 EBITDA, eyes overseas expansion push

2018-05-03 reuters
HONG KONG, May 3 (Reuters) - Macau casino operator Galaxy Entertainment Group posted a 36 percent rise in its first-quarter EBITDA due to resurgent demand from gamblers in the world’s biggest casino hub.
2282 SCHYF WYNMF MCHVF GXYEF GXYYY 0880 SJMHY 1128 0027 MCHVY 1928 SJMHF SCHYY WYNMY

0
Macau's Galaxy Entertainment posts 36 pct rise in Q1 EBITDA

2018-05-03 reuters
HONG KONG, May 3 (Reuters) - Macau casino operator Galaxy Entertainment Group posted a 36 percent rise in its first-quarter EBITDA due to resurgent demand from gamblers in the world’s biggest casino hub.
2282 SCHYF WYNMF MCHVF GXYEF GXYYY 0880 SJMHY 1128 0027 506186 MCHVY GLXYENT 1928 SJMHF SCHYY WYNMY

0
PAGCOR: Galaxy’s $500-M Boracay resort is on hold

2018-04-30 bworldonline
MANILA — The Philippines gaming regulator said a plan by Macau’s Galaxy Entertainment Group to build a $500-million integrated casino resort on a Philippine holiday island is on hold until the company can convince the president of its “advantages.”
0027 GXYEF GXYYY

0
‘Curious’ Cimatu barred from entering Boracay casino site

2018-04-28 newsinfo.inquirer.net
DENR Secretary Roy Cimatu holds a press briefing on Friday, April 27, 2018, after visiting several areas around Boracay after the implementation of the six-month closure, including the area where the Galaxy casino is expected to be built on. With him are Undersecretary Ernesto Adobo Jr., Undersecretary Miguel Cuna, among others (Photo by LYN RILLON / Philippine Daily Inquirer)
0027 GXYEF GXYYY

0
Just for laughs

2018-04-26 bworldonline
The gulf between what President Rodrigo Duterte says and what he does is raising already dangerous levels of cynicism about government and governance even among those who supported him in the 2016 presidential elections.
0027 GXYEF GXYYY

0
DENR orders 75 business owners to demolish illegal structures in Coron

2018-04-20 bworldonline
THE Department of Environment and Natural Resources (DENR) in a statement on Friday, April 20, said it has ordered 75 business owners to remove and self-demolish within 30 days their structures built on the waters and within the easement zones of Coron, Palawan.
0027 GXYEF GXYYY

0
Pagcor: Galaxy hasn’t backed out of Boracay

2018-04-18 newsinfo.inquirer.net
The country’s gaming regulator belied reports that Galaxy Entertainment Group would abandon its plan to build an integrated resort in Boracay, saying a final decision has yet to be made on the controversial issue.
0027 506186 GLXYENT GXYEF GXYYY

3
Wynn Resorts to Tighten Loan Safeguards as Macau Casinos Boom - Bloomberg

2018-04-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
1128 0027 WYNN WYNMF GXYEF GXYYY WYNMY

0
DOT: Galaxy Entertainment cancels plan to build casino in Boracay

2018-04-17 newsinfo.inquirer.net
PARTY ISLAND Boracay Island in Aklan province is known for its white sand beaches and vibrant night life and parties that have been drawing tourists year-round. INQUIRER file photo / LYN RILLON
0027 506186 GLXYENT GXYEF GXYYY

0
Boracay off-limits to Macau casino firm

2018-04-12 newsinfo.inquirer.net
HONG KONG—Macau’s Galaxy Entertainment Group Ltd. may open a casino in the Philippines but not on Boracay Island, according to presidential spokesperson Harry Roque.
0027 506186 GLXYENT GXYEF GXYYY

0
Palace insists ‘no new casino’ in Boracay; PAGCOR permits China firm to build one

2018-04-11 bworldonline
“No new casino will rise in Boracay,” Presidential Spokesperson Herminio Harry L. Roque, Jr. said on Wednesday, April 11, despite the existing provisional license granted recently by the Philippine Amusement and Gaming Corporation (PAGCOR) to a Chinese gaming company.
0027 GXYEF GXYYY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...